Summit bets $5B on Akeso, $500million upfront, and milestone payments of $4B for cancer therapy deal
- Dec 7, 2022
- 1 min read
Cambridge, MA, December 6, 2022 (Reuters) -- Summit Therapeutics Inc (SMMT.O) said on Tuesday it would license China-based Akeso Inc's (9926.HK) experimental cancer therapy in a deal worth up to $5 billion, sending its shares up 57% in premarket trade.
Read full article here.
Comments